Aerpio Announces Statistically Significant Topline Results from Razuprotafib Glaucoma Phase 2 Trial

NEXT STORY
Ziopharm Comments on Delay of WaterMill’s Stated Consent Deadline
PREV STORY
HOOKIPA Pharma Announces Closing of Public Offering of $80.9 Million of Common Stock and Preferred Stock, Including Full Exercise of Underwriters’ Option
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Immunicum AB (publ) Announces First Patient Treated in Phase Ib/II ILIAD Combination Trial

Press Release 11 February 2019 Immunicum AB (publ) Announces First Patient Treated in Phase ...

author_avatar
NASDAQ Market News

Nutra Pharma announces updates with EuroAmerican IP & BioArmor, LLC, a Service-Disabled Veteran-Owned Small Business for Sales through GoVets.com

Nutra Pharma is providing an update on the work of EuroAmerican IP, LLC to ...

author_avatar
NASDAQ Market News

INC Research Enhances Therapeutic Expertise With Key Promotions in General Medicine and CNS

RALEIGH, N.C., Aug. 25, 2015 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a ...

author_avatar
NASDAQ Market News